Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
October 23, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access -- -- BARHEMSYS is the first and only antiemetic...
Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting
October 04, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the dosing regimen that is being studied in the trial...
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
September 19, 2023 16:05 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
September 11, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease ---- The...
Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference
August 30, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform...
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
August 29, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for...
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
August 22, 2023 16:05 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
August 17, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 ---- Reflects strength of Eagle’s business and...
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
August 08, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share • Q2 2023 net income...
Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
August 01, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023...